Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGIR: azacitidine for recurrent IDH1/2-mutant glioma
2016-002822-35Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in glioma, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Progression-free survival at 6 months. Started Feb 2018; status: completed.
02
Drugs
azacitidine
03
Conditions
glioma
Beyond the preview
Go deeper on 2016-002822-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002822-35.